Tetraspanin CD9 Expression Predicts Sentinel Node Status in Patients with Cutaneous Melanoma.
cutaneous melanoma
lymph node metastasis
melanocytic nevi
prognostic marker
tetraspanin CD9
transendothelial invasion
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Apr 2022
26 Apr 2022
Historique:
received:
21
02
2022
revised:
22
04
2022
accepted:
24
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
The tetraspanin CD9 is considered a metastasis suppressor in many cancers, however its role is highly debated. Currently, little is known about CD9 prognostic value in cutaneous melanoma. Our aim was to analyse CD9 expression in melanocytic nevi and primary cutaneous melanomas through immunohistochemistry and immunofluorescence approaches to determine its correlation with invasiveness and metastatic potential. CD9 displayed homogeneous staining in all melanocytic nevi. In contrast, it showed a complete loss of reactivity in all thin melanomas. Interestingly, CD9 was re-expressed in 46% of intermediate and thick melanomas in small tumor clusters predominantly located at sites of invasion near or inside the blood or lymphatic vessels. The most notable finding is that all CD9 stained melanomas presented sentinel node positivity. Additionally, a direct association between CD9 expression and presence of distant metastasis was reported. Finally, we confirm that CD9 expression is consistent with an early protective role against tumorigenesis, however, our data endorse in melanoma a specific function of CD9 in vascular dissemination during late tumor progression. The presence of CD9 hotspots could be essential for melanoma cell invasion in lymphatic and endothelial vessels. CD9 could be a valid prognostic factor for lymph node metastasis risk.
Identifiants
pubmed: 35563166
pii: ijms23094775
doi: 10.3390/ijms23094775
pmc: PMC9103426
pii:
doi:
Substances chimiques
CD9 protein, human
0
Tetraspanin 29
0
Tetraspanins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Biol Chem. 2013 Jan 25;288(4):2118-31
pubmed: 23223239
Biosens Bioelectron. 2022 Feb 15;198:113828
pubmed: 34847362
Int J Mol Sci. 2021 Jun 15;22(12):
pubmed: 34203771
Int J Clin Exp Pathol. 2015 Mar 01;8(3):3054-61
pubmed: 26045817
Pigment Cell Melanoma Res. 2008 Apr;21(2):147-61
pubmed: 18426408
Oral Dis. 2013 Sep;19(6):620-7
pubmed: 23279259
Int J Cancer. 1993 Apr 22;54(1):37-43
pubmed: 8478146
Trends Cell Biol. 2009 Sep;19(9):434-46
pubmed: 19709882
Br J Dermatol. 2007 Dec;157(6):1212-6
pubmed: 17970806
JCO Precis Oncol. 2020;4:319-334
pubmed: 32405608
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33408092
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
J Clin Invest. 2000 May;105(9):1189-97
pubmed: 10791993
J Exp Med. 1993 May 1;177(5):1231-7
pubmed: 8478605
Exp Biol Med (Maywood). 2021 May;246(9):1121-1138
pubmed: 33601913
Eur J Cancer. 2020 Feb;126:141-158
pubmed: 31928887
Cancer. 2007 Jan 1;109(1):100-8
pubmed: 17146784
J Clin Oncol. 2010 May 10;28(14):2452-9
pubmed: 20368546
Contemp Oncol (Pozn). 2013;17(6):493-8
pubmed: 24592135
Eur J Surg Oncol. 2022 Feb;48(2):320-325
pubmed: 34794843
J Cancer Res Clin Oncol. 2021 Sep;147(9):2759-2764
pubmed: 33630139
Br J Dermatol. 2021 May;184(5):944-951
pubmed: 32844403
Eur J Dermatol. 2016 Aug 1;26(4):335-9
pubmed: 27436815
Nature. 2020 Sep;585(7823):113-118
pubmed: 32814895
Cancer. 1996 Aug 1;78(3):427-32
pubmed: 8697387
Dermatol Clin. 2019 Apr;37(2):159-168
pubmed: 30850038
Exp Cell Res. 2020 Jul 1;392(1):112009
pubmed: 32305326
Mod Pathol. 2003 Oct;16(10):1028-34
pubmed: 14559986
Nat Rev Cancer. 2009 Jan;9(1):40-55
pubmed: 19078974
Eur J Cancer. 2006 May;42(8):1181-7
pubmed: 16644201
Anticancer Res. 2015 Apr;35(4):2113-20
pubmed: 25862867
Am J Transl Res. 2020 Sep 15;12(9):5525-5537
pubmed: 33042435
Eur J Ophthalmol. 2022 Jan;32(1):612-619
pubmed: 33573425
J Cell Physiol. 2006 Jun;207(3):697-705
pubmed: 16523488
J Exp Clin Cancer Res. 2021 May 8;40(1):159
pubmed: 33964953
Cancer Biomark. 2018;21(4):781-786
pubmed: 29286918
Int J Cancer. 2021 Jun 15;148(12):2898-2905
pubmed: 33497469
J Invest Dermatol. 2005 Nov;125(5):1001-9
pubmed: 16297202
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
Ann Surg Oncol. 2008 Oct;15(10):2874-7
pubmed: 18648880
Mediators Inflamm. 2017;2017:3264217
pubmed: 28848246
Cancer Cell Int. 2021 Sep 7;21(1):472
pubmed: 34493282
Melanoma Res. 2020 Oct;30(5):433-442
pubmed: 32516239
Cancers (Basel). 2021 Jun 30;13(13):
pubmed: 34209415
Methods Enzymol. 2020;645:155-180
pubmed: 33565970
J Extracell Vesicles. 2022 Feb;11(2):e12197
pubmed: 35188342
Biochem Soc Trans. 2011 Apr;39(2):563-7
pubmed: 21428940
Clin Cancer Res. 2003 Dec 15;9(17):6426-31
pubmed: 14695144
N Engl J Med. 2021 Jan 7;384(1):72-79
pubmed: 33406334
Br J Cancer. 2018 Mar 20;118(6):867-877
pubmed: 29438363
Int J Immunopathol Pharmacol. 2007 Apr-Jun;20(2):325-33
pubmed: 17624244
Blood. 2001 Dec 15;98(13):3717-26
pubmed: 11739177
Nat Rev Cancer. 2014 Jan;14(1):49-60
pubmed: 24505619
Mol Carcinog. 2010 Jan;49(1):85-93
pubmed: 19777564